Abstract: Neuropilin-1 is henceforth a relevant target in cancer treatment, however way-of-action is remains partly elusive and the development of small inhibitory molecules is therefore required for its study. Here, the inventors report that two neuropilin small-sized antagonists (NRPa-47, NRPa-48), VEGF-A165/NRP-1 binding inhibitors, are able to decrease VEGF-Rs phosphorylation and to modulate their downstream cascades in triple negative breast cancer cell line (MDA-MB-231). In particular, the inventors showed for the first time, how NRPa may altered tumor cell signaling and contributed in the down-modulation of the cancer therapeutic key factor p38?-kinase phosphorylation. More importantly, the association of NRPa with a p38? inhibitor leads to additional and/or synergistic effect of these drugs (depending of the dose used) for significantly reducing breast cancer cell proliferation Thus, the efficient association of NRPa and p38?-kinase inhibitors are thus credible for the treatment of cancer.

Abstract: The present invention relates to a compound or a pharmaceutically acceptable salt thereof of formulae (I) and (II), and a pharmaceutical composition comprising such compound for use for treating a cancer, particularly a cancer overexpressing CXCR1 and CXCR2 receptors, such as medulloblastoma, head and neck and kidney cancer. The invention further relates to such compounds for use for treating macular degeneration.

Abstract: The invention concerns a method for estimating navigation date of a land vehicle, comprising steps of: recciving inertial data (100) acquired by an inertial sensor, receiving geometry and orientation parameters of a travelled road, integrating (106) the data on the basis of the parameters in order to produce navigation data comprising a movement of the vehicle relative to the road measured in a direction (Zr, Yr), the vehicle only being able to move in the direction within a bounded interval without leaving the road, estimating (108) an error affecting the navigation data by sol ing equations assuming that a difference between the calculated movement and a reference movement constitutes an error in the movement of the vehicle parallel to the direction, the reference movement having a value less than or equal to the length of the interval, correcting (110) the produced navigation data from the estimated error.

Abstract: The invention relates to a method for aligning an inertial navigation system borne by a static or quasi-static carrier, wherein: a plurality of alignment processes that are dimensioned for a plurality of amplitudes of movements of the carrier are implemented simultaneously with different alignment observation durations; a minimum observation duration that corresponds to the alignment observation duration for which the consistency of the alignment information obtained by means of alignment processes dimensioned for a given movement amplitude of the carrier is determined; and the alignment information is determined depending on alignment information determined for this minimum observation duration. The invention also relates to an associated inertial navigation system.

Abstract: The present invention concerns a method for detecting parasitic movements during static alignment of an inertial measurement unit (3), the method being characterised by steps of: receiving radio navigation measurements acquired (100) by a receiver (1) from signals previously transmitted by a set of radio navigation satellites (S), estimating (260) a movement of the inertial measurement unit from the acquired measurements, comparing (280) the estimated movement with a predefined threshold, indicating (290) a parasitic movement of the inertial measurement unit when the movement crosses the predefined threshold, in which the estimation (260) of the movement of the inertial measurement unit (3) from the acquired measurements comprises the following steps, implemented by the data processing unit for each satellite: calculating (262) a position variation from a phase of a first radio navigation signal transmitted by the satellite and received by the receiver at an initial reception time, and from a phase of a secon

Abstract: The invention concerns a method for controlling the integrity of the value of a piece of navigation information delivered by a merging/consolidation device including a plurality of processing modules. Each module generates a navigation solution from measurements coming from one or a plurality of separate navigation devices, which involves defining, for each processing module, a radius of protection, corresponding to a given probability of failure. The method includes defining at least one consolidated area that encompasses protection areas centered on the solution values that are output from the processing modules and that correspond to the radii of protection defined for these modules. The radius of protection of the merging/consolidation device for the probability of failure itself is defined to correspond to the consolidated area.

Abstract: The present invention concerns a method for detecting parasitic movements during static alignment of an inertial measurement unit (3), the method being characterised by steps of: receiving radio navigation measurements acquired (100) by a receiver (1) from signals previously transmitted by a set of radio navigation satellites (S), estimating (260) a movement of the inertial measurement unit from the acquired measurements, comparing (280) the estimated movement with a predefined threshold, indicating (290) a parasitic movement of the inertial measurement unit when the movement crosses the predefined threshold, in which the estimation (260) of the movement of the inertial measurement unit (3) from the acquired measurements comprises the following steps, implemented by the data processing unit for each satellite: calculating (262) a position variation from a phase of a first radio navigation signal transmitted by the satellite and received by the receiver at an initial reception time, and from a phase of a secon

Abstract: The invention concerns a method for controlling the integrity of the value of a piece of navigation information delivered by a merging/consolidation device including a plurality of processing modules. Each module generates a navigation solution from measurements coming from one or a plurality of separate navigation devices, which involves defining, for each processing module, a radius of protection, corresponding to a given probability of failure. The method includes defining at least one consolidated area that encompasses protection areas centered on the solution values that are output from the processing modules and that correspond to the radii of protection defined for these modules. The radius of protection of the merging/consolidation device for the probability of failure itself is defined to correspond to the consolidated area.

Abstract: The invention concerns a method for controlling the integrity of the value of a piece of navigation information delivered by a merging/consolidation device comprising a plurality of processing modules, each generating a navigation solution from measurements coming from one or a plurality of separate navigation devices, which involves defining, for each processing module, a radius of protection, corresponding to a given probability of failure, characterised in that it involves defining at least one consolidated area that encompasses protection areas centred on the solution values that are output from the processing modules and that correspond to the radii of protection defined for these modules, the radius of protection of said merging/consolidation device for said probability of failure itself being defined to correspond to said consolidated area.

Abstract: The present invention provides novel triazole derivatives as ghrelin analogue ligands of growth hormone secretagogue receptors according to formula (I) that are useful in the treatment or prophylaxis of physiological and/or pathophysiological conditions in mammals, preferably humans, that are mediated by GHS receptors. The present invention further provides GHS receptor antagonists and agonists that can be used for modulation of these receptors and are useful for treating above conditions, in particular growth retardation, cachexia, short-, medium- and/or long term regulation of energy balance; short-, medium- and/or long term regulation (stimulation and/or inhibition) of food intake; adipogenesis, adiposity and/or obesity; body weight gain and/or reduction; diabetes, diabetes type I, diabetes type II, tumor cell proliferation; inflammation, inflammatory effects, gastric postoperative ileus, postoperative ileus and/or gastrectomy (ghrelin replacement therapy).

Abstract: The invention relates to trisubstituted or tetrasubstituted imidazo[4,5b]pyridines, to their uses as well as to a process for manufacturing them. The compounds of the invention are imidazo[4,5b]pyridines. The first general synthesis of 3,5,7 imidazo[4,5b]pyridines is disclosed in the description. The invention founds application, in particular, in the pharmaceutical field.

Abstract: The present invention provides novel triazole derivatives as ghrelin analogue ligands of growth hormone secretagogue receptors according to formula (I) that are useful in the treatment or prophylaxis of physiological and/or pathophysiological conditions in mammals, preferably humans, that are mediated by GHS receptors. The present invention further provides GHS receptor antagonists and agonists that can be used for modulation of these receptors and are useful for treating above conditions, in particular growth retardation, cachexia, short-, medium- and/or long term regulation of energy balance; short-, medium- and/or long term regulation (stimulation and/or inhibition) of food intake; adipogenesis, adiposity and/or obesity; body weight gain and/or reduction; diabetes, diabetes type I, diabetes type II, tumor cell proliferation; inflammation, inflammatory effects, gastric postoperative ileus, postoperative ileus and/or gastrectomy (ghrelin replacement therapy).

Abstract: The present invention provides novel triazole derivatives as ghrelin analogue ligands of growth hormone secretagogue receptors according to formula (I) that are useful in the treatment or prophylaxis of physiological and/or pathophysiological conditions in mammals, preferably humans, that are mediated by GHS receptors. The present invention further provides GHS receptor antagonists and agonists that can be used for modulation of these receptors and are useful for treating above conditions, in particular growth retardation, cachexia, short-, medium- and/or long term regulation of energy balance; short-, medium- and/or long term regulation (stimulation and/or inhibition) of food intake; adipogenesis, adiposity and/or obesity; body weight gain and/or reduction; diabetes, diabetes type I, diabetes type II, tumor cell proliferation; inflammation, inflammatory effects, gastric postoperative ileus, postoperative ileus and/or gastrectomy (ghrelin replacement therapy).

Abstract: The invention relates to trisubstituted or tetrasubstituted imidazo[4,5b]pyridines, to their uses as well as to a process for manufacturing them. The compounds of the invention are imidazo[4,5b]pyridines. The first general synthesis of 3,5,7 imidazo[4,5b]pyridines is disclosed in the description. The invention founds application, in particular, in the pharmaceutical field.

Abstract: The present invention provides novel triazole derivatives as ghrelin analogue ligands of growth hormone secretagogue receptors according to formula (I) that are useful in the treatment or prophylaxis of physiological and/or pathophysiological conditions in mammals, preferably humans, that are mediated by GHS receptors. The present invention further provides GHS receptor antagonists and agonists that can be used for modulation of these receptors and are useful for treating above conditions, in particular growth retardation, cachexia, short-, medium- and/or long term regulation of energy balance; short-, medium- and/or long term regulation (stimulation and/or inhibition) of food intake; adipogenesis, adiposity and/or obesity; body weight gain and/or reduction; diabetes, diabetes type I, diabetes type II, tumor cell proliferation; inflammation, inflammatory effects, gastric postoperative ileus, postoperative ileus and/or gastrectomy (ghrelin replacement therapy).

Abstract: The present invention provides novel triazole derivatives as ghrelin analogue ligands of growth hormone secretagogue receptors according to formula (I) that are useful in the treatment or prophylaxis of physiological and/or pathophysiological conditions in mammals, preferably humans, that are mediated by GHS receptors. The present invention further provides GHS receptor antagonists and agonists that can be used for modulation of these receptors and are useful for treating above conditions, in particular growth retardation, cachexia, short-, medium- and/or long term regulation of energy balance; short-, medium- and/or long term regulation (stimulation and/or inhibition) of food intake; adipogenesis, adiposity and/or obesity; body weight gain and/or reduction; diabetes, diabetes type I, diabetes type II, tumor cell proliferation; inflammation, inflammatory effects, gastric postoperative ileus, postoperative ileus and/or gastrectomy (ghrelin replacement therapy).